{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '92', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.5', 'RECIST 1.1 Assessment of Disease', 'RECIST 1.1 will be used by BICR as the primary measure for assessment of tumor response', 'and date of PD, and as a basis for all protocol guidelines related to disease status (eg,', 'discontinuation of study intervention). Although RECIST 1.1 references a maximum of', '5 target lesions in total and 2 per organ, this protocol follows a maximum of 10 target lesions', 'and a maximum of 5 target lesions per organ, if clinically relevant to enable a broader', 'sampling of tumor burden.', 'If disease progression has been assessed by the investigator, the process continues as follows:', 'If participant is clinically stable, continue study intervention per protocol', '-', 'Resume imaging per protocol schedule (>4 weeks to next scan)', '-', 'Send scans to imaging vendor', '-', 'Continue local assessment', '-', 'Do not change investigator assessment of progression', '-', 'If subsequent scan(s) indicate progression, submit scan(s) to imaging vendor', 'If the participant is not clinically stable, best medical practice is to be applied', 'Before stopping study intervention or imaging or starting new anticancer therapy in a', 'participant who is clinically stable, communication with the Sponsor is required.', 'Investigator judgment will determine action', 'Note: the reconsent addendum may be signed any time after investigator-assessed', 'progression is identified, but must be signed prior to starting study intervention.', '-', 'Obtain scans locally per original protocol schedule', '-', 'Do not send scans to imaging vendor', 'For the purpose of this decision process, lack of clinical stability is defined as:', 'Unacceptable toxicity', 'Clinical signs or symptoms indicating clinically significant disease progression', 'Decline in performance status', 'Rapid disease progression or threat to vital organs or critical anatomical sites (eg,', 'CNS metastasis, respiratory failure due to tumor compression, spinal cord', 'compression) requiring urgent alternative medical intervention', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '93', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.6', 'iRECIST Assessment of Disease', 'NOTE: After amendment 007-06, imaging obtained on study will be submitted to the', 'imaging vendor but these will not be assessed, verification of PD is no longer needed', 'before treatment discontinuation, and posttreatment imaging is no longer required.', 'This section has been updated accordingly.', 'iRECIST is based on RECIST 1.1 but adapted to account for the unique tumor response seen', 'with immunotherapeutic drugs. iRECIST will be used by the investigator to assess tumor', 'response and progression and make treatment decisions [Seymour, L., et al 2017]. When', 'clinically stable, participants will continue study intervention beyond RECIST 1.1 PD with', 'continuous assessment of response according to the rules outlined in Appendix 6. iRECIST', 'reflects some participants can have a transient tumor flare after the start of immunotherapy,', 'then experience subsequent disease response. This data will be captured in the clinical', 'database.', 'Clinical stability is defined as the following:', 'Absence of symptoms and signs indicating clinically significant PD', 'No decline in ECOG performance status', 'No requirements for intensified management, including increased analgesia,', 'radiation, or other palliative care', 'Any participant deemed clinically unstable should be discontinued from study intervention at', 'site-assessed first radiologic evidence of PD and is not required to have repeat tumor scans', 'for confirmation of PD by iRECIST.', 'If the investigator decides to continue treatment, the participant may continue to receive', 'study intervention and the tumor assessment should be repeated 4 to 8 weeks later to confirm', 'PD by iRECIST, per investigator assessment. Scans should continue to be sent in to the', 'central imaging vendor', 'If repeat scans do not confirm PD per iRECIST, as assessed by the investigator, and the', 'participant continues to be clinically stable, study intervention may continue and follow the', 'regular scan schedule. If PD is confirmed, participants will be discontinued from study', 'intervention.', 'If a participant has iRECIST-confirmed radiographic progression (iCPD) as defined in', 'Appendix 6, study intervention should be discontinued; however, if the participant is', 'achieving a clinically meaningful benefit, an exception to continue study intervention may be', 'considered following consultation with the Sponsor. In this case, if study intervention is', 'continued, tumor scans should continue to be performed following the intervals as outlined in', 'Section 1 and submitted to the central imaging vendor.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}